Скачать или смотреть Targeting Cortisol in Type 2 Diabetes: Results from the CATALYST trial

NEW! The CATALYST Trial Breakthrough: Could Cortisol Blockade Be the Secret Weapon for Tough Type 2 Diabetes?

Uncontrolled type 2 diabetes despite everything? The CATALYST study points to a hidden culprit: excess cortisol! Discover fresh clinical insights and practical management pearls for endocrinologists and diabetologists. Scroll for timestamps!

Key Study Reference:
DeFronzo RA, Fonseca V, Aroda VR, Auchus RJ, Bailey T, Bancos I, et al. Diabetes Care. 2025;dc251055.

***

Timestamps / Video Chapters
0:00 – The Frustration: Why some patients stay uncontrolled
0:16 – What if you’re missing a diagnosis? Secondary causes revealed
0:37 – The shocking stat: 23.8% have hidden hypercortisolism!
0:65 – How cortisol sabotages diabetes management
0:84 – Introduction to Mifepristone: Not just a reproductive drug!
1:36 – The CATALYST Trial: Design and major outcomes
1:69 – Results: 1.32% drop in HbA1c in toughest patients
2:10 – Bonus: Over 5kg weight loss & slimmer waists
2:18 – Does dose & duration matter? Comparing CATALYST vs. Gubbi
2:78 – Side effects: What you MUST watch out for
2:84 – Management tips: Proactive protocols and education
3:57 – Stepwise action plan for clinicians
4:84 – Who is the IDEAL candidate for this therapy?
5:31 – Take-home: Should dexamethasone suppression be routine?

***

Why This Matters:
Potential game-changer for a quarter of your hardest-to-treat diabetes patients!
Highlights importance of screening for covert cortisol excess
Real-world challenges: side effects and strict monitoring

***

Like, subscribe & share for more viral endocrine updates!
Comment below: Does the CATALYST result change your clinical approach? Would you try GR blockade in your practice?

#Diabetes #Endocrinology #CATALYSTtrial #Cortisol #Mifepristone #ClinicalPearls #ViralMedEd